Pruritus in Female Patients

Lambert, Julien

doi:10.1155/2014/541867

Cited by 22 publications

(19 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The improvement in pruritus and burning was considered clinically relevant as they are very distressing and persistent, and frequently they do not resolve without treatment. 20 …”

Section: Discussionmentioning

confidence: 99%

Efficacy, acceptability and tolerability of Zelesse® for the treatment of non-specific vulvovaginitis in paediatric patients: The NINESSE Study

García

Rodriguez²,

Palomo³

et al. 2018

J Int Med Res

View full text Add to dashboard Cite

ObjectiveTo evaluate the efficacy, tolerability and acceptability of Zelesse®, an intimate hygiene wash solution, in the relief of the symptoms and signs of non-specific vulvovaginitis in paediatric patients.MethodsThe NINESSE Study was a prospective, observational, multicentre study involving females aged 2–8 years who attended paediatric offices with symptoms suggestive of non-specific vulvovaginitis. They were administered Zelesse® as a single treatment for 15 ± 5 days. Pruritus, burning, dysuria, erythema, leucorrhoea and oedema were evaluated before and after treatment.ResultsA total of 71 paediatric patients were enrolled in the study (mean ± SD age, 4.5 ± 1.9 years). The most significant effects were observed for pruritus and burning, where 98.4% (62 of 63) and 96.9% (63 of 65) of the patients improved after treatment, respectively. Zelesse® demonstrated a beneficial effect on dysuria, erythema, leucorrhoea and oedema. The effects on the symptoms and signs were observed within the first week of treatment; although 44.9% (31 of 69) of patients experienced improvements after 2–3 days. Zelesse® was well accepted and tolerated by most patients. No serious adverse events were reported.ConclusionsZelesse® was very effective for the relief of the symptoms and signs of non-specific vulvovaginitis, in particular pruritus, burning and erythema, in females aged 2–8 years.

show abstract

“…The improvement in pruritus and burning was considered clinically relevant as they are very distressing and persistent, and frequently they do not resolve without treatment. 20 …”

Section: Discussionmentioning

confidence: 99%

Efficacy, acceptability and tolerability of Zelesse® for the treatment of non-specific vulvovaginitis in paediatric patients: The NINESSE Study

García

Rodriguez²,

Palomo³

et al. 2018

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…For example, women are more likely to report the localised itching as occurring in attacks and have more chronic scratch lesions (96). The changing levels of oestrogen and progesterone in post-menopausal women lead to changes in hydration and collagen content, which can lead to pruritic inflammatory vulvovaginal dermatoses (97).…”

Section: Additional Considerations For the Management Of Itchmentioning

confidence: 99%

Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions

Yosipovitch¹,

Miséry²,

Proksch³

et al. 2019

Acta Derm Venereol

118

View full text Add to dashboard Cite

Itch is a common symptom of many skin barrier-related dermatoses and can severely impact quality of life. However, there are a limited number of effective anti-itch topical therapies currently available and several unmet needs not addressed by current itch management strategies. As our knowledge of the mechanisms underlying itch has improved, several novel therapies have recently emerged that can be incorporated into existing regimens to enhance itch therapy and management. Here, we summarise research and current opinion on available topical therapies and give recommendations for the optimal management of itch. Barrier damage, dry skin and itch are intricately linked and form the basis of many common skin diseases. Damage from environmental insults, or genetic or inflammatory causes, can impair the skin barrier, resulting in an increase in transepidermal water loss and activation of itch-associated nerve fibres. The itch-scratch cycle can perpetuate skin barrier damage and itch. Topical therapeutic strategies are utilised to overcome dry skin and itch, primarily in the form of emollients. Recent advances in our understanding of the mechanisms underlying itch have enabled the development of new topical therapies, which may be incorporated into existing treatment regimes. Ultimately, treatment of dry skin and itch must be highly tailored to the individual according to their needs.

show abstract

“…Although probably rare, it may sometimes be worthwhile to consider neuropathic itch as a possible cause. This could be associated with sacral spinal compression, postherpetic neuralgia and diabetic neuropathy . The itch–scratch–itch cycle plays a pivotal role in maintaining chronicity of the condition.…”

Section: Lichen Simplex Chronicusmentioning

confidence: 99%

2016 European guideline for the management of vulval conditions

Meijden

Boffa

Harmsel

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

Vulval conditions may present to a variety of clinicians, such as dermatologists, gynaecologists and general practitioners.Women with these conditions are best managed by a multidisciplinary approach, which includes clear referral pathways between disciplines or access to a specialist multidisciplinary vulval service. Informed consent is a prerequisite for all examinations, investigations and treatments. Consent is particularly important for intimate examinations of the anogenital area, and a chaperone should be offered in all cases. All efforts should be made to maintain a patient's dignity. Depending on symptoms and risk factors, screening for sexually transmitted infections (STI) should be considered. If the patient presents with vulval itch, particularly if also complaining of increased vaginal discharge, vulvaginal candidiasis should be excluded. Sexual dysfunction should be considered in all patients with vulval complaints, either as the cause of the symptoms or secondary to symptoms, and assessed if appropriate. This guideline covers several aspects, such as diagnosis and treatment, of the more common vulval conditions (relatively) often encountered at vulval clinics, i.e. vulval dermatitis (eczema), psoriasis, lichen simplex chronicus, lichen sclerosus, lichen planus, vulvodynia and vulval intraepithelial neoplasia (VIN).

show abstract

Pruritus in Female Patients

Cited by 22 publications

References 32 publications

Efficacy, acceptability and tolerability of Zelesse® for the treatment of non-specific vulvovaginitis in paediatric patients: The NINESSE Study

Efficacy, acceptability and tolerability of Zelesse® for the treatment of non-specific vulvovaginitis in paediatric patients: The NINESSE Study

Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions

2016 European guideline for the management of vulval conditions

Contact Info

Product

Resources

About